Alexandria Pharmaceuticals results, Q1 2025
Net profit, assets, equity and cash flow for Q1 2025, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit98.51 millionEGP · +66.5% vs the same period a year earlier
Total assets1.51 billionEGP · +39.6% vs the same period a year earlier
Shareholders' equity893 millionEGP · +24.2% vs the same period a year earlier
Operating cash flow126 millionEGP · +132.7% vs the same period a year earlier
In short
- Alexandria Pharmaceuticals's net profit for Q1 2025 was about 98.51 million EGP, up +66.5% from 59.18 million EGP in Q1 2024.
- Total assets at the end of Q1 2025 were about 1.51 billion EGP, and shareholders' equity about 893 million EGP.
- Operating cash flow for Q1 2025 was positive at 126 million EGP.
Key lines against the same period a year earlier
This periodQ1 2024Change
Net profit98.51 million59.18 million+66.5%
Gross profit171 million387 million−56.0%
Total assets1.51 billion1.08 billion+39.6%
Total liabilities619 million365 million+69.9%
Shareholders' equity893 million719 million+24.2%
Total liabilities and equity1.51 billion1.08 billion+39.6%
Operating cash flow126 million54.26 million+132.7%
Investing cash flow-5.09 million-8.58 million+40.7%
Financing cash flow-723 thousand-122 thousand−491.6%
Net change in cash120 million45.56 million+164.3%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Alexandria Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy